Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study

Ariella Bar-Gil Shitrit; Ami Ben Ya'Acov; Dan Meir Livovsky; Tzufit Cuker; Rivka Farkash; Aviya Hoyda; Tami Granot; Irit Avni-Biron; Adi Lahat; Eran Goldin; Sorina Grisaru-Granovsky

doi:10.14309/ajg.0000000000000186

Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study

Ariella Bar-Gil Shitrit^*
, Ami Ben Ya'Acov
, Dan Meir Livovsky
, Tzufit Cuker
, Rivka Farkash
, Aviya Hoyda
, Tami Granot
, Irit Avni-Biron
, Adi Lahat
, Eran Goldin
, Sorina Grisaru-Granovsky

^*Corresponding author for this work

Institute for Medical Research Israel-Canada (IMRIC)

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

OBJECTIVES:Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established.DESIGN:Data of 330 consecutive pregnancies with IBD was prospectively collected.RESULTS:Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy.DISCUSSION:Although further study is needed, VDZ appears of low risk during pregnancy.

Original language	English
Pages (from-to)	1172-1175
Number of pages	4
Journal	American Journal of Gastroenterology
Volume	114
Issue number	7
DOIs	https://doi.org/10.14309/ajg.0000000000000186
State	Published - Jul 2019

Bibliographical note

Publisher Copyright:
© 2020 American Institute of Physics Inc.. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.14309/ajg.0000000000000186

Cite this

Bar-Gil Shitrit, A., Ben Ya'Acov, A., Livovsky, D. M., Cuker, T., Farkash, R., Hoyda, A., Granot, T., Avni-Biron, I., Lahat, A., Goldin, E., & Grisaru-Granovsky, S. (2019). Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. American Journal of Gastroenterology, 114(7), 1172-1175. https://doi.org/10.14309/ajg.0000000000000186

@article{0754ea058c524c388b99cdeaab8ef95d,

title = "Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study",

abstract = "OBJECTIVES:Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established.DESIGN:Data of 330 consecutive pregnancies with IBD was prospectively collected.RESULTS:Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not na{\"i}ve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy.DISCUSSION:Although further study is needed, VDZ appears of low risk during pregnancy.",

author = "\{Bar-Gil Shitrit\}, Ariella and \{Ben Ya'Acov\}, Ami and Livovsky, \{Dan Meir\} and Tzufit Cuker and Rivka Farkash and Aviya Hoyda and Tami Granot and Irit Avni-Biron and Adi Lahat and Eran Goldin and Sorina Grisaru-Granovsky",

year = "2019",

month = jul,

doi = "10.14309/ajg.0000000000000186",

language = "אנגלית",

volume = "114",

pages = "1172--1175",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Wolters Kluwer Health",

number = "7",

}

Bar-Gil Shitrit, A, Ben Ya'Acov, A, Livovsky, DM, Cuker, T, Farkash, R, Hoyda, A, Granot, T, Avni-Biron, I, Lahat, A, Goldin, E & Grisaru-Granovsky, S 2019, 'Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study', American Journal of Gastroenterology, vol. 114, no. 7, pp. 1172-1175. https://doi.org/10.14309/ajg.0000000000000186

TY - JOUR

T1 - Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate

T2 - A First Prospective Comparison Study

AU - Bar-Gil Shitrit, Ariella

AU - Ben Ya'Acov, Ami

AU - Livovsky, Dan Meir

AU - Cuker, Tzufit

AU - Farkash, Rivka

AU - Hoyda, Aviya

AU - Granot, Tami

AU - Avni-Biron, Irit

AU - Lahat, Adi

AU - Goldin, Eran

AU - Grisaru-Granovsky, Sorina

PY - 2019/7

Y1 - 2019/7

N2 - OBJECTIVES:Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established.DESIGN:Data of 330 consecutive pregnancies with IBD was prospectively collected.RESULTS:Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy.DISCUSSION:Although further study is needed, VDZ appears of low risk during pregnancy.

AB - OBJECTIVES:Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established.DESIGN:Data of 330 consecutive pregnancies with IBD was prospectively collected.RESULTS:Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy.DISCUSSION:Although further study is needed, VDZ appears of low risk during pregnancy.

UR - https://www.scopus.com/pages/publications/85069271147

U2 - 10.14309/ajg.0000000000000186

DO - 10.14309/ajg.0000000000000186

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 30920987

AN - SCOPUS:85069271147

SN - 0002-9270

VL - 114

SP - 1172

EP - 1175

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 7

ER -

Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this